Showing results (21-30 of 96) with videos related to

Sort By:
Pageof 10
Biomedicines|January 25, 2025
Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet's Disease from Immunological and Clinical PerspectivesMakoto Naganuma, Mitsuhiro Takeno, Aykut Ferhat Çelik, et al.
Intestinal Research|April 22, 2020
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysisToshifumi Hibi, Isao Kamae, Philippe Pinton, et al.
Clinical and Diagnostic Laboratory Immunology|July 10, 2004
Development of a macroarray to specifically analyze immunological gene expression in swineTerence N Ledger, Philippe Pinton, Dorothée Bourges, et al.
Journal of Toxicology and Environmental Health. Part B, Critical Reviews|June 22, 2017
Impact of mycotoxins on the intestine: are mucus and microbiota new targets?Hervé Robert, Delphine Payros, Philippe Pinton, et al.
The Journal of Nutrition|September 24, 2010
Deoxynivalenol impairs porcine intestinal barrier function and decreases the protein expression of claudin-4 through a mitogen-activated protein kinase-dependent mechanismPhilippe Pinton, Cornelia Braicu, Jean-Philippe Nougayrede, et al.
Archives of Toxicology|September 25, 2016
Toxicology of deoxynivalenol and its acetylated and modified formsDelphine Payros, Imourana Alassane-Kpembi, Alix Pierron, et al.
Current Topics in Microbiology and Immunology|September 28, 2018
Overview and Comparison of Intestinal Organotypic Models, Intestinal Cells, and Intestinal Explants Used for Toxicity StudiesMarc Maresca, Philippe Pinton, El Hassan Ajandouz, et al.
Scientific Reports|June 2, 2026
A machine-learning approach to predict additional treatment after Bacillus Calmette-Guérin induction in non-muscle-invasive bladder cancerPhilippe Pinton, Haruna Kawano, Oliver Patschan, et al.
Toxicology Letters|March 11, 2008
Ingestion of deoxynivalenol (DON) contaminated feed alters the pig vaccinal immune responsesPhilippe Pinton, Francesc Accensi, Erwan Beauchamp, et al.
Inflammatory Bowel Diseases|January 25, 2025
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLSJessica R Allegretti, Paul Feuerstadt, Whitfield L Knapple, et al.
Pageof 10